U.S. Stem Cell (USRM) 10-Q 9 May 14 2014 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2014	6-May-14
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'BIOHEART, INC.	'
Entity Central Index Key	'0001388319	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--12-31	'
Document Type	'10-Q	'
Document Period End Date	31-Mar-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	466,396,016

Condensed_Balance_Sheets

Condensed Balance Sheets (USD $)	Mar. 31, 2014	Dec. 31, 2013
Current assets:	'	'
Cash and cash equivalents	$218,984	$46,227
Accounts receivable, net	48,754	19,913
Prepaid and other	1,674	784
Total current assets	269,412	66,924
Property and equipment, net	8,192	9,055
Other assets	10,012	10,160
Total assets	287,616	86,139
Current liabilities:	'	'
Accounts payable	2,513,125	2,382,267
Accrued expenses	2,368,377	4,480,335
Advances, related party	403,957	416,198
Deposits	478,286	478,286
Subordinated debt, related party	1,500,000	1,500,000
Notes payable, related party	2,179,737	2,241,477
Notes payable, net of debt discount	1,966,946	1,930,841
Total current liabilities	11,410,428	13,429,404
Long term debt:	'	'
Derivative liability	1,051,196	403,811
Stockholders' deficit:	'	'
Preferred stock, par value $0.001; 20,000,000 shares authorized, 20,000,000 issued and outstanding	20,000	20,000
Common stock, par value $0.001; 950,000,000 shares authorized, 420,920,157 and 379,787,745 shares issued and outstanding as of March 31, 2014 and December 31, 2013, respectively	420,920	379,788
Additional paid in capital	104,678,615	103,819,119
Common stock subscription	210,000	215,000
Deficit accumulated during development stage	-117,503,543	-118,180,983
Total stockholders' deficit	-12,174,008	-13,747,076
Total liabilities and stockholders' deficit	$287,616	$86,139

Condensed_Balance_Sheets_Paren

Condensed Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Balance Sheets [Abstract]	'	'
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares issued	20,000,000	20,000,000
Preferred stock, shares outstanding	20,000,000	20,000,000
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	950,000,000	950,000,000
Common stock, shares issued	420,920,157	379,787,745
Common stock, shares outstanding	420,920,157	379,787,745

Condensed_Statements_of_Operat

Condensed Statements of Operations (Unaudited) (USD $)	3 Months Ended		176 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014
Statements of Operations [Abstract]	'	'	'
Revenue	$322,572	$4,192	$1,688,297
Cost and operating expenses:	'	'	'
Cost of sales	94,446	'	677,181
Research and development	9,857	163,974	65,329,892
Marketing, general and administrative	838,329	370,533	39,943,996
Impairment of investment	'	'	58,695
Depreciation and amortization	863	769	900,967
Total operating expenses	943,495	535,276	106,910,731
Net loss from operations	-620,923	-531,084	-105,222,434
Other income (expenses):	'	'	'
Development revenues	'	'	117,500
Gain on settlement of debt	2,093,632	1,004,224	3,117,071
Loss on change of fair value of derivative liability	-489,371	-640,589	-365,423
Interest income	'	'	762,277
Other income	'	939	344,821
Interest expense	-305,898	-352,383	-16,257,355
Total other income (expenses)	1,298,363	12,191	-12,281,109
Net income (loss) before income taxes	677,440	-518,893	-117,503,543
Income taxes (benefit)	'	'	'
NET INCOME (LOSS)	$677,440	($518,893)	($117,503,543)
Net income (loss) per common share, basic	$0.00	($0.00)	'
Net income (loss) per common share, diluted	$0.00	($0.00)	'
Weighted average number of common shares outstanding, basic	401,553,577	185,421,093	'
Weighted average number of common shares outstanding, diluted	498,696,292	185,421,093	'

Condensed_Statement_of_Stockho

Condensed Statement of Stockholders' Deficit (Unaudited) (USD $)	Total	Preferred stock	Common stock	Additional Paid in Capital	Subscription Receivable	Deficit Accumulated During Development Stage
Beginning Balance at Dec. 31, 2013	($13,747,076)	$20,000	$379,788	$103,819,119	$215,000	($118,180,983)
Beginning Balance, Shares at Dec. 31, 2013	'	20,000,000	379,787,745	'	'	'
Common stock issued in settlement of accounts payable	107,474	'	6,751	100,723	'	'
Common stock issued in settlement of accounts payable, Shares	'	'	6,750,781	'	'	'
Common stock issued in connection with settlement of other debt	194,044	'	7,166	186,878	'	'
Common stock issued in connection with settlement of other debt, Shares	'	'	7,166,214	'	'	'
Proceeds from issuance of common stock	371,000	'	27,215	348,785	-5,000	'
Proceeds from issuance of common stock, Shares	'	'	27,215,417	'	'	'
Proceeds from exercise of warrants	6,000	'	'	6,000	'	'
Fair value of vesting warrants issued in connection with joint venture	22,546	'	'	22,546	'	'
Stock based compensation	194,564	'	'	194,564	'	'
Net income	677,440	'	'	'	'	677,440
Balance at Mar. 31, 2014	($12,174,008)	$20,000	$420,920	$104,678,615	$210,000	($117,503,543)
Balance, Shares at Mar. 31, 2014	'	20,000,000	420,920,157	'	'	'

Condensed_Statements_of_Cash_F

Condensed Statements of Cash Flows (Unaudited) (USD $)	3 Months Ended		176 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'	'
Net income (loss)	$677,440	($518,893)	($117,503,543)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'
Depreciation and amortization	863	769	900,967
Bad debt expense	10,000	'	176,266
Discount on convertible debt	93,604	124,838	2,073,854
Loss on change in fair value of derivative liability	489,371	640,589	365,423
Gain on settlement of debt	-2,093,632	-1,004,224	-3,117,071
Non cash payment of interest	164,757	123,578	664,524
Amortization of warrants issued in exchange for licenses and intellectual property	'	'	5,413,156
Amortization of warrants issued in connection with notes payable	'	'	5,437,604
Amortization of loan costs	'	'	1,228,717
Related party notes payable issued for services rendered	'	'	500,000
Warrants issued in exchange for services	'	'	285,659
Warrants issued in exchange for forbearance agreement	'	'	430,213
Warrants issued in connection with joint venture agreement	22,546	'	22,546
Equity instruments issued in connection with R&D agreement	'	'	360,032
Equity instruments issued in connection with settlement agreement	'	'	3,381,629
Common stock issued in connection with accounts payable	'	'	759,316
Common stock issued in exchange for services	'	'	1,567,673
Common stock issued in connection with amounts due to guarantors of Bank of America loan	'	'	69,159
Common stock issued in exchange for distribution rights and intellectual property	'	'	99,997
Preferred stock issued in settlement of forbearance agreement	'	'	274,050
Warrants issued in connection with accounts payable	'	'	7,758
Stock based compensation	194,564	19,632	10,271,081
(Increase) decrease in:	'	'	'
Receivables	-38,841	-362	-60,019
Inventory	'	62,953	'
Prepaid and other current assets	-742	-37,827	33,006
Other assets	'	1	-28,854
Increase (decrease) in:	'	'	'
Accounts payable	172,786	-12,509	3,373,406
Accrued expenses	49,522	55,077	7,412,998
Deferred revenue	'	'	465,287
Net cash used in operating activities	-257,762	-546,378	-75,135,166
CASH FLOWS FROM INVESTING ACTIVITIES:	'	'	'
Acquisitions of property and equipment	'	'	-909,158
Net cash used by investing activities	'	'	-909,158
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'	'
Bank overdraft	'	-89	'
Proceeds from issuance of common stock, net	371,000	400,000	65,679,689
Proceeds from (payments for) initial public offering of common stock, net	'	'	1,447,829
Proceeds from subordinated related party note	'	'	3,000,000
Payment of note payable	'	'	-3,000,000
Proceeds from notes payable, related party	'	'	505,000
(Repayments (proceeds) from related party advances	-10,241	180,500	1,072,751
Proceeds from exercise of stock options and warrants	6,000	'	299,749
Proceeds from notes payable	127,500	205,000	12,163,750
Repayments of notes payable	-63,740	'	-3,686,192
Payment of loan costs	'	'	-1,219,268
Net cash provided in financing activities	430,519	785,411	76,263,308
Net increase in cash and cash equivalents	172,757	239,033	218,984
Cash and cash equivalents, beginning of period	46,227	'	'
Cash and cash equivalents, end of period	218,984	239,033	218,984
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION	'	'	'
Interest paid	84,986	103,969	2,790,810
Income taxes paid	'	'	'
Non cash financing activities:	'	'	'
Common stock issued in settlement of notes payable	194,044	19,500	5,240,138
Common stock issued in settlement of accounts payable	107,475	146,740	278,691
Common stock issued in settlement of related party notes payable	'	'	397,750
Common stock issued in settlement of interest and penalties in connection with convertible debt	'	'	150,815
Preferred stock issued in settlement of notes payable	'	'	70,000
Reclassification from notes payable to related party advances	'	'	$544,267

Significant_Accounting_Policie

Significant Accounting Policies	3 Months Ended
	Mar. 31, 2014
Significant Accounting Policies [Abstract]	'
SIGNIFICANT ACCOUNTING POLICIES	'
	NOTE 1 – SIGNIFICANT ACCOUNTING POLICIES
	A summary of the significant accounting policies applied in the presentation of the accompanying unaudited condensed financial statements follows:
	General
	The accompanying unaudited condensed financial statements of Bioheart, Inc., (the “Company”), have been prepared in accordance with the rules and regulations (S-X) of the Securities and Exchange Commission (the “SEC”) and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.
	In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The results from operations for the three month period ended March 31, 2014 are not necessarily indicative of the results that may be expected for the year ended December 31, 2014. The unaudited condensed financial statements should be read in conjunction with the December 31, 2013 financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K.
	Basis and business presentation
	Bioheart, Inc. (the “Company”) was incorporated under the laws of the State of Florida in August, 1999. The Company is in the development stage, as defined by Accounting Standards Codification subtopic 915-10, Development Stage Entities (“ASC 915-10”) and is the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. To date, the Company has not generated significant sales revenues, has incurred expenses, and has sustained losses. Consequently, its operations are subject to all the risks inherent in the establishment of a new business enterprise. For the period from inception through March 31, 2014, the Company has accumulated a deficit through its development stage of $117,503,543.
	Revenue Recognition
	The Company recognizes revenue in accordance with Accounting Standards Codification subtopic 605-10, Revenue Recognition (“ASC 605-10”) which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded.
	At the time of each transaction, management assesses whether the fee associated with the transaction is fixed or determinable and whether or not collection is reasonably assured. The assessment of whether the fee is fixed or determinable is based upon the payment terms of the transaction. If a significant portion of a fee is due after our normal payment terms or upon implementation or client acceptance, the fee is accounted for as not being fixed or determinable and revenue is recognized as the fees become due or after implementation or client acceptance has occurred. Collectability is assessed based on a number of factors, including past transaction history with the client and the creditworthiness of the client.
	Revenues for test kits and equipment sold are not recorded until test kits are delivered. Revenues from trainings are not recorded until the completion of the training. Any cash received as a deposit for trainings are recorded by the company as a liability.
	Unbilled revenue is revenue that is recognized but is not currently billable to the customer pursuant to contractual terms. In general, such amounts become billable in accordance with predetermined payment schedules, but recognized as revenue as services are performed. Amounts included in unbilled revenue are expected to be collected within one year and are included within current assets.
	Comprehensive Income
	The Company does not have any items of comprehensive income in any of the periods presented.
	Net Income (loss) per Common Share, basic and diluted
	The Company has adopted Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”) specifying the computation, presentation and disclosure requirements of earnings per share information. Basic loss per share has been calculated based upon the weighted average number of common shares outstanding. Stock options, warrants and shares issuable upon conversion of notes payable have been excluded as common stock equivalents in the diluted loss per share because their effect is anti-dilutive on the computation for the three months ended March 31, 2013. Fully diluted shares outstanding were 498,696,292 and 222,688,816 for the three months ended March 31, 2014 and 2013, respectively.
	Stock Based Compensation
	The Company follows Accounting Standards Codification subtopic 718-10, Compensation (“ASC 718-10”) which requires that all share-based payments to both employees and non-employees be recognized in the income statement based on their fair values. (See note 10).
	As of March 31, 2014, there were outstanding stock options to purchase 43,650,856 shares of common stock, 16,650,856 shares of which were vested.
	Concentrations of Credit Risk
	The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. The financial stability of these institutions is periodically reviewed by senior management.
	As of March 31, 2014, two customers represented 26% and 25% (total of 51%) of the Company’s accounts receivable.
	As of December 31, 2013, three customers represented 20%, 20% and 36% (total 76%) of the Company’s accounts receivable.
	For the three months ended March 31, 2014, the Company’s revenues earned from the sale of products and services were $322,572, of which two customers represented 17% and 10% of the Company’s revenues.
	Research and Development
	The Company accounts for research and development costs in accordance with Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved as defined under the applicable agreement. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $9,857 and $163,974 for the three months ended March 31, 2014 and 2013, respectively; and $65,329,892 from August 12, 1999 (date of inception) to March 31, 2014.
	Fair Value
	Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities, and short-term borrowings, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed.
	The company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value. Neither of these statements had an impact on the Company’s financial position, results of operations nor cash flows.
	Reliance on Key Personnel and Consultants
	The Company has 4 full-time employees and 1 part-time employee. The Company is heavily dependent on the continued active participation of these current executive officers, employees and key consultants. The loss of any of the senior management or key consultants could significantly and negatively impact the business until adequate replacements can be identified and put in place.
	Derivative Instrument Liability
	The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At March 31, 2014 and December 31, 2013, the Company did not have any derivative instruments that were designated as hedges.
	Recent Accounting Pronouncements
	There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s unaudited condensed financial position, results of operations or cash flows.

Going_Concern_Matters

Going Concern Matters	3 Months Ended
	Mar. 31, 2014
Going Concern Matters [Abstract]	'
GOING CONCERN MATTERS	'
	NOTE 2 – GOING CONCERN MATTERS
	The accompanying unaudited condensed financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying unaudited condensed financial statements, during three months ended March 31, 2014, the Company incurred an operating loss of $620,923 and used $257,762 in cash for operating activities. As of March 31, 2014, the Company had a working capital deficit (current liabilities in excess of current assets) of approximately $11.1 million. These factors among others may indicate that the Company will be unable to continue as a going concern for a reasonable period of time.
	The Company’s existence is dependent upon management’s ability to develop profitable operations and to obtain additional funding sources. There can be no assurance that the Company’s financing efforts will result in profitable operations or the resolution of the Company’s liquidity problems. The accompanying statements do not include any adjustments that might result should the Company be unable to continue as a going concern.

Property_and_Equipment

Property and Equipment	3 Months Ended
	Mar. 31, 2014
Property and Equipment [Abstract]	'
PROPERTY AND EQUIPMENT	'
	NOTE 3 — PROPERTY AND EQUIPMENT
	Property and equipment as of March 31, 2014 and December 31, 2013 is summarized as follows:
		March 31,			December 31,
		2014			2013
	Laboratory and medical equipment	$	352,358		$	352,358
	Furniture, fixtures and equipment		125,634			125,634
	Computer equipment		39,525			39,525
	Leasehold improvements		362,046			362,046
			879,563			879,563
	Less accumulated depreciation and amortization		(871,371	)		(870,508	)
		$	8,192		$	9,055
	Property and equipment are recorded on the basis of cost. For financial statement purposes, property, plant and equipment are depreciated using the straight-line method over their estimated useful lives.
	Expenditures for repair and maintenance which do not materially extend the useful lives of property and equipment are charged to operations. When property or equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are removed from the respective accounts with the resulting gain or loss reflected in operations. Management periodically reviews the carrying value of its property and equipment for impairment in accordance with the guidance for impairment of long lived assets.

Accrued_Expenses

Accrued Expenses	3 Months Ended
	Mar. 31, 2014
Accrued Expenses [Abstract]	'
ACCRUED EXPENSES	'
	NOTE 4 — ACCRUED EXPENSES
	Accrued expenses consisted of the following as of March 31, 2014 and December 31, 2013:
		March 31,		December 31,
		2014		2013
	License and royalty fees	$	—	$	2,122,130
	Amounts payable to the Guarantors of the Company’s loan agreement with Bank of America and Seaside Bank, including fees and interest		1,356,013		1,373,775
	Interest payable on notes payable		757,669		714,180
	Vendor accruals and other		127,189		120,692
	Employee commissions, compensation, etc.		127,506		149,558
		$	2,368,377	$	4,480,335
	In June 2000, the Company had entered into an agreement with William Beaumont Hospital, or WBH, pursuant to which WBH granted the Company a worldwide, exclusive, non-sublicenseable license to two U.S. method patents covering the inducement of human adult myocardial cell proliferation in vitro, or the WBH IP. The term of the agreement was for the life of the patents, which expire in 2015. The Company did not use this license in any of thier technologies or made any payments to WBH other than the initial payment to acquire the license. On April 2, 2014, the Company received confirmation that it has no obligation under the patent license agreement, WBH agreed to terminate the patent license agreement pursuant to a termination letter dated March 3, 2014, and WBH agreed to terminate the patent license agreement.
	Accordingly, the Company recognized approximately $2,122,130 in settlement of debt which represents the accumulative accrual and related interest from past years under the 2000 patent license agreement.
	During the three months ended March 31, 2014, the Company issued an aggregate of 6,750,781 shares of its common stock in settlement of outstanding accounts payable. In connection with the issuance, the Company incurred $65,548 loss in settlement of debt.

Standby_Equity_Distribution_Ag

Standby Equity Distribution Agreement	3 Months Ended
	Mar. 31, 2014
Standby Equity Distribution Agreement [Abstract]	'
STANDBY EQUITY DISTRIBUTION AGREEMENT	'
	NOTE 5 – STANDBY EQUITY DISTRIBUTION AGREEMENT
	On November 2, 2011, the Company and Greystone Capital Partners (“Greystone”) had entered into a Standby Equity Distribution Agreement (the “Agreement”).  Pursuant to the Agreement, Greystone had agreed to provide the Company with up to $1.0 million of funding for the 24-month period following the date a registration statement of the Company’s common stock is declared effective by the SEC (the “Equity Line”).  The registration statement went effective on February 10, 2012. The Agreement automatically terminated on the first of April, 2014 (the first day of the month next following the second (2nd) anniversary of the Effective Date).

Notes_Payable

Notes Payable	3 Months Ended
	Mar. 31, 2014
Notes Payable [Abstract]	'
NOTES PAYABLE	'
	NOTE 6 – NOTES PAYABLE
	Notes payable were comprised of the following as of March 31, 2014 and December 31, 2013:
		March 31,			December 31,
		2014			2013
	Seaside Bank note payable.	$	980,000		$	980,000
	August 2008 Unsecured Promissory Note		500,000			500,000
	Hunton & Williams notes payable		384,972			384,972
	Asher notes payable		183,000			143,000
	Daniel James Management note payable		35,000
	Fourth Man, LLC note payable		35,000			35,000
	Total notes payable		2,117,972			2,042,972
	Less unamortized debt discount		(151,027	)		(112,131	)
	Total notes payable net of unamortized debt discount	$	1,966,946		$	1,930,841
	Seaside Bank
	On October 25, 2010, the Company entered into a Loan Agreement with Seaside National Bank and Trust for a $980,000 loan at 4.25% per annum interest that was used to refinance the Company’s loan with Bank of America. The obligation is guaranteed by certain shareholders of the Company. The Company renewed the loan with Seaside National Bank and Trust during the first quarter of 2014 to extend the maturity date to December 23, 2015.
	August 2008 Unsecured Promissory Note
	On August 20, 2008, the Company borrowed $1.0 million from a third party pursuant to the terms of an unsecured Promissory Note and Agreement. Outstanding principal and interest on the loan, which accrues at the rate of 13.5% per annum, is payable in one balloon payment upon the Company’s repayment of the BlueCrest Loan, which is scheduled to mature in May 2010, however the Company is not obligated to make payments until BlueCrest Loan is paid off. In the event the Company completes a private placement of its common stock and/or securities exercisable for or convertible into its common stock which generates at least $19.0 million of gross proceeds, the Company may prepay, without penalty, all outstanding principal and interest due under the loan using the same type of securities issued in the subject private placement. Because repayment of the loan could occur within 12 months from the date of the balance sheet, the Company has classified this loan as short term.
	Subject to certain conditions, at the end of each calendar quarter during the time the loan is outstanding, the Company may, but is not required to, pay all or any portion of the interest accrued but unpaid as of such date with shares of its common stock. In April 2009, as consideration for the authorization to amend certain documents related to the Note, the Company issued to the Note holder a warrant to purchase 451,053 shares of common stock at an exercise price of $0.5321 per share.
	The warrant, which became exercisable immediately upon issuance, has a ten year term. This warrant had a fair value of $195,694, which was accounted for as additional paid in capital and reflected as a component of debt discount and has been fully amortized as interest expense ratably over the term of the loan.
	In 2013, 1,000,000 shares of common stock were issued to the debt holder, in exchange for $500,000 in principal and $598,125 of accrued interest relating to a previously issued note resulting in a gain of $1,078,625. A gain of $1,078,625 was included in the net gain on settlement of debt and trade payables on the statement of operations. As of March 31, 2014 the principle of this note was $500,000.
	Hunton & Williams Notes
	At March 31, 2014 and December 31, 2013, the Company has two outstanding notes payable with interest at 8% per annum due at maturity. The two notes, $61,150 and $323,822 are payable in one balloon payment upon the date the Noteholder provides written demand, however the Company is not obligated to make payments until the Northstar (or successor) Loan is paid off.
	Asher Notes (During this year)
	During the three months ended March 31, 2014, the Company entered into a Securities Purchase Agreements with Asher Enterprises, Inc. (“Asher”) or affiliates, for the sale of 8% convertible notes in aggregate principal amount of $97,500 (the “Asher Notes”).
	The Asher Notes bear interest at the rate of 8% per annum. As of the quarter ended March 31, 2014 all interest and principal must be repaid nine months from the issuance date, the last note due December 26, 2014. The Notes are convertible into common stock, at Asher’s option, at a 45% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion. The Company has identified the embedded derivatives related to the Asher Notes.
	These embedded derivatives included certain conversion features and reset provision. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of Asher Notes and to fair value as of each subsequent reporting date which at March 31, 2014 was $153,564. At the inception of the Asher Notes, the Company determined the aggregate fair value of $214,346 of the embedded derivatives.
	Daniel James Management
	On February 19, 2014, the Company entered into a Securities Purchase Agreements with Daniel James Management (“Daniel”) for the sale of 8% convertible note in principal amount of $35,000 (the “Daniel Note”).
	The Daniel Note bear interest at the rate of 8% per annum with all interest and principal due February 28, 2015. The Daniel Note is convertible into common stock, at holder’s option, at a 47% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion. The Company has identified the embedded derivatives related to the Daniel Note. These embedded derivatives included certain conversion features and reset provision.
	The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of Daniel Note and to fair value as of each subsequent reporting date which at March 31, 2014 was $63,343. At the inception of the Daniel Note, the Company determined the aggregate fair value of $63,343 of the embedded derivatives.
	The fair value of the embedded derivatives of the Asher Notes and Daniel Note, was determined using the Binomial Option Pricing Model based on the following assumptions: (1) dividend yield of 0%; (2) expected volatility of 158.19% to 181.73%, (3) weighted average risk-free interest rate of 0.03% to 0.15%, (4) expected lives of 0.03 to 1.00 years, and (5) estimated fair value of the Company’s common stock from $0.001 to $0.0447 per share. The initial fair value of the embedded debt derivative of $292,257 was allocated as a debt discount up to the proceeds of the note ($127,500) with the remainder ($164,757) charged to current period operations as interest expense. For the three months ended March 31, 2014 and 2013, the Company amortized an aggregate of $93,604 and $124,838 of debt discounts to current period operations as interest expense, respectively.

Related_Party_Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2014
Related Party Transactions [Abstract]	'
RELATED PARTY TRANSACTIONS	'
	NOTE 7 — RELATED PARTY TRANSACTIONS
	Advances
	As of March 31, 2014 and December 31, 2013, the Company officers and directors have provided advances in the aggregate of $403,957 and $416,198 respectively, for working capital purposes. The advances are unsecured, due on demand and non-interest bearing.
	Notes payable-related party
	Northstar Biotechnology Group, LLC
	On February 29, 2012, a note issued to BlueCrest Master Fund Limited was assigned to Northstar Biotechnology Group, LLC (“Northstar”), owned partly by certain directors and existing shareholders of the Company, including Dr. William P. Murphy Jr., Dr. Samuel Ahn and Charles Hart. At the date of the assignment, the principal amount of the BlueCrest note was $544,267.
	On March 30, 2012, the Company and Northstar agreed to extend until May 1, 2012 the initial payment date for any and all required monthly under the Note, such that the first of the four monthly payments required under the Note will be due and payable on May, 2012 and all subsequent payments will be due on a monthly basis thereafter commencing on June 1, 2012, and to waive any and all defaults and/or events of default under the Note with respect to such payments. As of September 30, 2012, the Company was in default, however, subsequent to September 30, 2012, the Company renegotiated the terms of the Note, Northstar has agreed to suspend the requirement of principal payments by the Company and allow payment of interest-only in common stock.
	On September 21, 2012, the Company issued 5,000,000 common stock purchase warrants to Northstar that was treated as Additional interest expense upon issuance.
	On October 1, 2012, the Company and Northstar entered into a limited waiver and forbearance agreement providing a recapitalized new note balance comprised of all sums due Northstar with a maturity date extended perpetually. The Company agreed to issue 5,000,000 shares of Series A Convertible Preferred Stock and 10,000,000 of common stock in exchange for $210,000 as payment towards outstanding debt, default interest, penalties, professional fees outstanding and due Northstar. In addition, the Company executed a security agreement granting Northstar a lien on all patents, patent applications, trademarks, service marks, copyrights and intellectual property rights of any nature, as well as the results of all clinical trials, know-how for preparing Myoblasts, old and new clinical data, existing approved trials, all right and title to Myoblasts, clinical trial protocols and other property rights.
	In addition, the Company granted Northstar a perpetual license on products as described for resale, relicensing and commercialization outside the United States. In connection with the granted license, Northstar shall pay the Company a royalty of up to 8% on revenues generated.
	Effective October 1, 2012, the effective interest rate was 12.85% per annum. The parties agreed, as of February 28, 2013, to reduce the interest rate to 7% per annum.
	In connection with the consideration paid, Northstar waived, from the effective date through the earlier of termination or expiration of the agreement, satisfaction of the obligations as described in the forbearance agreement. In 2012, 5,000,000 shares of Series A Convertible Preferred Stock were approved to be issued. In addition, the Company is obligated to issue additional preferred stock equal in lieu of payment of cash of accrued and unpaid interest on each six month anniversary of the effective date (October 1, 2012). In lieu of the initial two payments in preferred stock, the parties have determined to modify the voting rights of the Series A Convertible Preferred Stock from 20 votes per share on matters to be voted on by the common stock holders to 25 votes per share on matters to be voted on by the common stock holders and all prior and subsequent payments of interest will be in common stock. The Company is required to issue additional shares of its common stock (as amended), in lieu of cash, each six month anniversary of the effective date for any accrued and unpaid interest.
	As of March 31, 2014 and December 31, 2013, the principle of this note was $362,000.
	Officer and Director Notes
	At March 31, 2014 and December 31, 2013, the Company has outstanding notes payable to officers and directors with interest at 8% per annum due at maturity. The three subordinated notes, $125,000, $100,000 and $140,000 were previously due on October 22, 2012, November 30, 2012 and June 4, 2011 respectively, and are unsecured. The Company is not obligated to make payment until Northstar loan is paid off.
	On October 9, 2012, the Company issued an aggregate of $1,278,324 of promissory notes due October 9, 2013 to officers and directors in settlement of outstanding advances and accrued compensation (currently in default). The promissory notes bear interest of 5% per annum and due at maturity.
	On September 30, 2013, the Company issued an aggregate of 15,350,876 shares of its common stock in settlement of $175,000 of related party notes payable.
	On August 1, 2013, the Company issued an aggregate of $500,000 promissory notes due on demand to officers and employee in settlement of accrued compensation. The promissory notes bear interest of 5% per annum and due at various maturity dates. During the three months ended March 31, 2014, the Company paid off $63,740 of the outstanding promissory notes. The principle outstanding balance of these notes as of March 31, 2014 is $349,413.
	Subordinated debt, related party
	As of March 31, 2014 and December 31, 2013, the Company officers and directors have provided notes in aggregate of $1,500,000. The notes are at from 4.75% to 8% per annum and are due upon payoff of the Northstar note payable described above.

Derivative_Liabilities

Derivative Liabilities	3 Months Ended
	Mar. 31, 2014
Derivative Liabilities [Abstract]	'
DERIVATIVE LIABILITIES	'
	NOTE 8 — DERIVATIVE LIABILITIES
	Reset warrants
	On October 1, 2012, in connection with the forbearance agreement with Northstar as discussed in Note 7 above, the Company issued an aggregate of 15,000,000 common stock purchase warrants to purchase the Company’s common stock with an exercise price of $0.014 per share for ten years with anti-dilutive (reset) provisions.
	The Company has identified embedded derivatives related to the issued warrants. These embedded derivatives included certain and anti-dilutive (reset) provisions. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date and to fair value as of each subsequent reporting date.
	At March 31, 2014, the fair value of the reset provision of $666,485 was determined using the Binomial Option Pricing model with the following assumptions: dividend yield: 0%; volatility: 173.72%; risk free rate: 2.73%; and expected life: 8.50 years. The Company recorded a loss on change in derivative liabilities of $519,630 during the three months ended March 31, 2014.
	Convertible notes
	In 2013 and the three months ended March 31, 2014, the Company issued convertible notes (see Note 6 above).
	These notes are convertible into common stock, at holders’ option, at a discount to the market price of the Company’s common stock. The Company has identified the embedded derivatives related to these notes relating to certain anti-dilutive (reset) provisions. These embedded derivatives included certain conversion features. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of Asher Note and to fair value as of each subsequent reporting date.
	The fair value of the embedded derivatives at March 31, 2014, in the amount of $384,711, was determined using the Binomial Option Pricing Model based on the following assumptions: (1) dividend yield of 0%; (2) expected volatility of 173.72%, (3) weighted average risk-free interest rate of 0.03 to 0.13%, (4) expected lives of 0.03 to 0.74 years, and (5) estimated fair value of the Company’s common stock of $0.0447 per share. The Company recorded a gain on change in derivative liabilities of $30,259 during the three months ended March 31, 2014.
	Based upon ASC 840-15-25 (EITF Issue 00-19, paragraph 11) the Company has adopted a sequencing approach regarding the application of ASC 815-40 to its outstanding convertible notes. Pursuant to the sequencing approach, the Company evaluates its contracts based upon earliest issuance date.
	At March 31, 2014, the aggregate derivative liabilities was valued at $1,051,196, the Company believes an event under the contract that would create an obligation to settle in cash or other current assets is remote and has classified the obligation as a long term liability.

Stockholders_Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2014
Stockholders' Equity [Abstract]	'
STOCKHOLDERS' EQUITY	'
	NOTE 9 – STOCKHOLDERS’ EQUITY
	Preferred stock
	On August 17, 2012, the board of directors designated 5,000,000 shares of preferred stock as Series A Convertible Preferred Stock which was increased to 20,000,000 shares of preferred stock as Series A Convertible Preferred Stock. Each share of preferred stock is convertible into equal number of common shares at the option of the holder; entitled to 20 votes on all matters presented to be voted by the holders of common stock; upon event of liquidation, entitled to amount equal to stated value plus any accrued and unpaid dividends or other fees before distribution to junior securities. In lieu of the initial two payments due to Northstar, the parties have determined to modify the voting rights of the Series A Convertible Preferred Stock from 20 votes per share on matters to be voted on by the common stock holders to 25 votes per share on matters to be voted on by the common stock holders (see Note 7 above).
	Common stock
	During the three months ended March 31, 2014, the Company issued an aggregate of 6,750,781 shares of its common stock in settlement of outstanding accounts payable. In connection with the issuance, the Company incurred a loss on settlement of debt of $65,548.
	During the three months ended March 31, 2014, the Company issued an aggregate of 7,166,214 shares of its common stock for the conversion of $57,500 of convertible notes payable and related accrued interest of $2,300.

Stock_Option_and_Warrants

Stock Option and Warrants	3 Months Ended
	Mar. 31, 2014
Stock Options and Warrants [Abstract]	'
STOCK OPTIONS AND WARRANTS	'
	NOTE 10 — STOCK OPTIONS AND WARRANTS
	Stock Options
	In December 1999, the Board of Directors and shareholders adopted the 1999 Officers and Employees Stock Option Plan, or the Employee Plan, and the 1999 Directors and Consultants Stock Option Plan, or the Director Plan. The Employee Plan and the Director Plan are collectively referred to herein as the Plans. The Plans are administered by the Board of Directors and the Compensation Committee. The objectives of the Plans include attracting and retaining key personnel by encouraging stock ownership in the Company by such persons. In February 2010, the Directors & Consultants Plan was amended to extend the termination date of the Plan to December 1, 2011.
	In April 1, 2013, the Board of Directors approved, subject to shareholder approval, the establishment of the Bioheart 2013 Omnibus Equity Compensation Plan, or the “2013 Omnibus Plan”. The 2013 Omnibus Plan reserves up to fifty million shares of common stock for issuance.
	A summary of options at March 31, 2014 and activity during the three months then ended is presented below:
		Shares			Weighted-		Weighted-
					Average		Average
					Exercise Price		Remaining
							Contractual
							Term (in years)
	Options outstanding at January 1, 2013		7,853,376		$	0.67	8.2
	Granted		17,400,000		$	0.016	9.9
	Exercised		—		$
	Forfeited/Expired		(1,340,433	)	$	1.08
	Options outstanding at December 31, 2013		23,912,943		$	0.15	9
	Granted		19,800,000		$	0.019	9.1
	Exercised		—
	Forfeited/Expired		(62,087	)	$	1.08
	Options outstanding at March 31, 2014		43,650,856		$	0.08	9.3
	Options exercisable at March 31, 2014		16,650,856		$	0.18	8.9
	Available for grant at March 31, 2014		12,800,000
	The following information applies to options outstanding and exercisable at March 31, 2014:
		Options Outstanding								Options Exercisable
		Shares			Weighted-		Weighted-		Shares			Weighted-
					Average		Average					Average
					Remaining		Exercise					Exercise
					Contractual		Price					Price
					Term
	$0.00 – $0.70		43,090,000			9.4	$	0.03			16,090,000		$	0.04
	$0.71 – $1.28		162,286			4.2	$	0.8			162,286		$	0.8
	$5.25 – $5.67		373,858			2.1	$	5.55			373,858		$	5.55
	$7.69		24,712			2.3	$	7.69			24,712		$	7.69
			43,650,856			9.3	$	0.08			16,650,856		$	0.18
	On February 24, 2014, the Company issued an aggregate 15,000,000 options to purchase the Company’s common stock at $0.019 per share to officers, vesting at 25% immediately and the remainder over approximately 42 months, exercisable over 10 years. The aggregate fair value of $282,597, determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: 0%; Volatility: 163.63% and Risk free rate: 2.75%.
	On February 24, 2014, the Company issued an aggregate 4,800,000 options to purchase the Company’s common stock at $0.019 per share to officers, vesting immediately and exercisable over 10 years. The aggregate fair value of $90,431, determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: 0%; Volatility: 163.63% and Risk free rate: 2.75%.
	The fair value of all options vesting during the three months ended March 31, 2014 and 2013 of $194,565 and $19,632, respectively, was charged to current period operations.
	Warrants
	A summary of common stock purchase warrants at March 31, 2014 and activity during the three months then ended is presented below:
		Shares			Weighted-		Weighted-
					Average		Average
					Exercise		Remaining
					Price		Contractual
							Term (in
							years)
	Outstanding at January 1, 2013		74,073,322		$	0.37		4.5
	Issued		50,350,536		$	0.16		9.2
	Exercised		—		$	0
	Forfeited		-6,345,002		$	0.38
	Outstanding at December 31, 2013		118,078,856		$	0.22		6.3
	Issued		32,292,783		$	0.017		8.4
	Exercised		—		$	—
	Expired		(2,314,575	)	$	0.18
	Outstanding at March 31, 2014		148,057,064		$	0.17		6.7
	Exercisable at March 31, 2014		102,401,650		$	0.13		5.7
	The following information applies to common stock purchase warrants outstanding and exercisable at March 31, 2014:
		Warrants Outstanding								Warrants Exercisable
		Shares			Weighted-		Weighted-			Shares		Weighted-
					Average		Average					Average
					Remaining		Exercise					Exercise
					Contractual		Price					Price
					Term
	$0.01 – $0.50		141,807,931			6.7	$	0.02			97,696,967		$	0.02
	$0.52 – $0.68		2,699,675			5.1	$	0.58			2,699,675		$	0.58
$0.70 – $1.62		848,176			5.8	$	0.71			848,176		$	0.71
$5.67 – $7.69		2,701,282			8.6	$	7.55			1,156,832		$	7.35
		148,057,064			6.7	$	0.17			102,401,650		$	0.13
In conjunction with the authorized issuance of common stock, the Company granted 24,292,783 common stock purchase warrants during the three months ended March 31, 2014.
During the three months ended March 31, 2014, the Company issued an aggregate of 8,000,000 warrants in connection with a joint venture agreement dated March 10, 2014. The warrants are exercisable at $0.0217 for four years vesting from June 8, 2014 through March 10, 2015. During the three months ended March 31, 2014, the Company charged $22,546 to current period operations for the vesting portion.

Commiments_and_Contingencies

Commiments and Contingencies	3 Months Ended
	Mar. 31, 2014
Commitments and Contingencies [Abstract]	'
COMMITMENTS AND CONTINGENCIES	'
	NOTE 11 — COMMITMENTS AND CONTINGENCIES
	Joint Venture Agreement
	On March 10, 2014, the Company entered a joint-venture or profits sharing agreement (the Agreement) with Global Stem Cells, Group, LLC and its subsidiaries whereby both parties will participate in marketing for obtaining patients and provide physician training for stem cell treatments under the names of “Regenestem” and “Stem Cell Training”, respectively. In addition, each party will be responsible for selling equipment and kit to existing and previous customers. Profits are divided on a fifty/fifty basis with distribution within 10 days of the accounting for patients and physician training and 30 day with sales of equipment and kits.
	In consideration of Global Stem Cell Group, LLC’s participation, the Company issued an aggregate of 8,000,000 warrants to purchase the Company’s common stock for four years at $0.0217 per share with 2,000,000 warrants vesting 90 days from the effective date, 2,000,000 vesting on each anniversary date for three years. During the three months ended March 31, 2014, the Company charged $22,546 to current period operations for the vesting portion.
	William Beaumont Hospital
	In June 2000, the Company entered into an agreement with William Beaumont Hospital, or WBH, pursuant to which WBH granted to the Company worldwide, exclusive, non-sublicenseable license to two U.S. method patents covering the inducement of human adult myocardial cell proliferation in vitro, or the WBH IP. The term of the agreement is for the life of the patents, which expire in 2015. The Company did not use this license in any of our technologies. The Company had not made any payments to WBH other than the initial payment to acquire the license. The Company has received confirmation that it has no obligation under the patent license agreement and WBH agreed to terminate the patent license agreement. (See Note 4)
	Accordingly, the Company will recognize approximately $2,122,000 in settlement of debt which represents the accumulative accrual and related interest from past years under the 2000 patent license agreement.
	Contingency for Registration of the Company’s common stock
	The Company believes that it may have issued options to purchase common stock to certain of its employees, directors and consultants in California in violation of the registration or qualification provisions of applicable California securities laws. As a result, the Company intends to make a rescission offer to these persons. The Company will make this offer to all persons who have a continuing right to rescission, which it believes to include two persons. In the rescission offer, in accordance with California law, the Company will offer to repurchase all unexercised options issued to these persons at 77% of the option exercise price multiplied by the number of option shares, plus interest at the rate of 7% from the date the options were granted. Based upon the number of options that were subject to rescission as of December 31, 2009, assuming that all such options are tendered in the rescission offer, the Company estimated that its total rescission liability would be up to approximately $371,000. However, as the Company believes there is only a remote likelihood the rescission offer will be accepted by any of these persons in an amount that would result in a material expenditure by the Company, no liability was recorded as of March 31, 2014 or December 31, 2013.
	Litigation
	The Company is subject to other legal proceedings that arise in the ordinary course of business. In the opinion of management, as of March 31, 2014, the amount of ultimate liability with respect to such matters, if any, in excess of applicable insurance coverage, is not likely to have a material impact on the Company’s business, financial position, results of operations or liquidity. However, as the outcome of litigation and other claims is difficult to predict significant changes in the estimated exposures could exist.
	Consulting agreements
	On November 20, 2013, the Company entered into an investment banking agreement with Cassel Salpeter & Co. (“CSC”), who will act as exclusive third party financial advisor in connection with investment banking matters. The term of the Investment Banking Agreement shall be for a period of twenty four months unless terminated or extended in accordance with its terms. For these services, CSC will receive a one-time $25,000 fee, $5,000 monthly fees and 5,207,630 ten year common stock purchase warrants, exercisable at $.0113 and applicable consideration in the event the closing of a Mezzanine Financing consisting of non-convertible subordinated debt and/or sale of equity securities. The Company will also reimburse CSC for its reasonable out-of-pocket expenses associated with the services provided pursuant to the Investment Banking Agreement. As of March 31, 2014 and December 31, 2013, the Company accrued $46,317 and $32,424 under the agreement, respectively.

Fair_Value_Measurement

Fair Value Measurement	3 Months Ended
	Mar. 31, 2014
Fair Value Measurement [Abstract]	'
FAIR VALUE MEASUREMENT	'
	NOTE 12 — FAIR VALUE MEASUREMENT
	The Company adopted the provisions of Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) on January 1, 2008. ASC 825-10 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. ASC 825-10 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825-10 establishes three levels of inputs that may be used to measure fair value:
	Level 1 – Quoted prices in active markets for identical assets or liabilities.
	Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities.
	Level 3 – Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities.
	All items required to be recorded or measured on a recurring basis are based upon level 3 inputs.
	To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement.
	Upon adoption of ASC 825-10, there was no cumulative effect adjustment to beginning retained earnings and no impact on the financial statements.
	The carrying value of the Company’s cash and cash equivalents, accounts receivable, accounts payable, short-term borrowings (including convertible notes payable), and other current assets and liabilities approximate fair value because of their short-term maturity.
	As of March 31, 2014 or December 31, 2013, the Company did not have any items that would be classified as level 1 or 2 disclosures.
	The Company recognizes its derivative liabilities as level 3 and values its derivatives using the methods discussed in notes 7 and 9. While the Company believes that its valuation methods are appropriate and consistent with other market participants, it recognizes that the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date. The primary assumptions that would significantly affect the fair values using the methods discussed in Notes 7 and 9 are that of volatility and market price of the underlying common stock of the Company.
	As of March 31, 2013 and December 31, 2013, the Company did not have any derivative instruments that were designated as hedges.
	The derivative liability as of March 31, 2014, in the amount of $1,051,196 has a level 3 classification.
	The following table provides a summary of changes in fair value of the Company’s Level 3 financial liabilities as of March 31, 2014:
		Excess Share			Warrant			Debt
		Derivative			Liability			Derivative
	Balance, December 31, 2012	$	390,048			221,179		$	—
	Total (gains) losses
	Initial fair value of debt derivative at note issuance					—			673,219
	Initial fair value of derivative relating to reset warrants		—			—			—
	Mark-to-market at December 31, 2013:		84.906			(74,324	)		(39,761	)
	Transfers out of Level 3 upon increase in authorized shares		(474,954	)		—			—
	Transfers out of Level 3 upon conversion and settlement of notes								(376,502	)
	Balance, December 31, 2013	$	—		$	146,855		$	256,956
	Total (gains) losses
	Initial fair value of debt derivative at note issuance		—			—			292,257
	Mark-to-market at March 31, 2014:		—			519,630			(30,259	)
	Transfers out of Level 3 upon conversion of notes payable		—			—			(134,243	)
	Balance, March 31, 2014	$	—		$	666,485		$	384,711
	Net (Loss) Gain for the period included in earnings relating to the liabilities held at March 31, 2014	$	—		$	(519,630	)	$	30,259
	Fluctuations in the Company’s stock price are a primary driver for the changes in the derivative valuations during each reporting period. The Company’s stock price increased approximately 447% from December 31, 2013 to March 31, 2014. As the stock price increases for each of the related derivative instruments, the value to the holder of the instrument generally increases, therefore increasing the liability on the Company’s balance sheet. Additionally, stock price volatility is one of the significant unobservable inputs used in the fair value measurement of each of the Company’s derivative instruments. The simulated fair value of these liabilities is sensitive to changes in the Company’s expected volatility. Increases in expected volatility would generally result in a higher fair value measurement.

Subsequent_Events

Subsequent Events	3 Months Ended
	Mar. 31, 2014
Subsequent Events [Abstract]	'
SUBSEQUENT EVENTS	'
	NOTE 13 — SUBSEQUENT EVENTS
	In April 2014, the Company issued an aggregate of 3,839,832 shares of its common stock for services rendered valued at $43,250.
	In April 2014, the Company issued 5,263,315 shares of its common stock in settlement of related party advances of $100,000.
	In April, 2014, the Company issued 1,002,808 shares of its common stock in settlement of common stock subscriptions of $50,000
	In April 2014, the Company issued 274,681 shares of its common stock as settlement of six months accrued interest on the Northstar note obligation.
	In April 2014, the Company issued 18,383,774 shares of its common stock for service rendered valued at $180,511.
	In April 2014, the Company issued an aggregate of 4,793,268 shares of its common stock in settlement of $67,500 convertible notes payable and $2,700 accrued interest.
	In April 2014, the Company issued 11,918,181 shares of its common stock in connection with the exercise of warrants. Proceeds received was $136,000, of which $6,000 during the three months ended March 31, 2014.

Significant_Accounting_Policie1

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2014
Significant Accounting Policies [Abstract]	'
Basis and business presentation	'
	Basis and business presentation
	Bioheart, Inc. (the “Company”) was incorporated under the laws of the State of Florida in August, 1999. The Company is in the development stage, as defined by Accounting Standards Codification subtopic 915-10, Development Stage Entities (“ASC 915-10”) and is the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. To date, the Company has not generated significant sales revenues, has incurred expenses, and has sustained losses. Consequently, its operations are subject to all the risks inherent in the establishment of a new business enterprise. For the period from inception through March 31, 2014, the Company has accumulated a deficit through its development stage of $117,503,543.
Revenue Recognition	'
	Revenue Recognition
	The Company recognizes revenue in accordance with Accounting Standards Codification subtopic 605-10, Revenue Recognition (“ASC 605-10”) which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded.
	At the time of each transaction, management assesses whether the fee associated with the transaction is fixed or determinable and whether or not collection is reasonably assured. The assessment of whether the fee is fixed or determinable is based upon the payment terms of the transaction. If a significant portion of a fee is due after our normal payment terms or upon implementation or client acceptance, the fee is accounted for as not being fixed or determinable and revenue is recognized as the fees become due or after implementation or client acceptance has occurred. Collectability is assessed based on a number of factors, including past transaction history with the client and the creditworthiness of the client.
	Revenues for test kits and equipment sold are not recorded until test kits are delivered. Revenues from trainings are not recorded until the completion of the training. Any cash received as a deposit for trainings are recorded by the company as a liability.
	Unbilled revenue is revenue that is recognized but is not currently billable to the customer pursuant to contractual terms. In general, such amounts become billable in accordance with predetermined payment schedules, but recognized as revenue as services are performed. Amounts included in unbilled revenue are expected to be collected within one year and are included within current assets.
Comprehensive Income	'
	Comprehensive Income
	The Company does not have any items of comprehensive income in any of the periods presented.
Net Income (loss) per Common Share, basic and diluted	'
	Net Income (loss) per Common Share, basic and diluted
	The Company has adopted Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”) specifying the computation, presentation and disclosure requirements of earnings per share information. Basic loss per share has been calculated based upon the weighted average number of common shares outstanding. Stock options, warrants and shares issuable upon conversion of notes payable have been excluded as common stock equivalents in the diluted loss per share because their effect is anti-dilutive on the computation for the three months ended March 31, 2013. Fully diluted shares outstanding were 498,696,292 and 222,688,816 for the three months ended March 31, 2014 and 2013, respectively.
Stock based compensation	'
	Stock Based Compensation
	The Company follows Accounting Standards Codification subtopic 718-10, Compensation (“ASC 718-10”) which requires that all share-based payments to both employees and non-employees be recognized in the income statement based on their fair values. (See note 10).
	As of March 31, 2014, there were outstanding stock options to purchase 43,650,856 shares of common stock, 16,650,856 shares of which were vested.
Concentrations of Credit Risk	'
	Concentrations of Credit Risk
	The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. The financial stability of these institutions is periodically reviewed by senior management.
	As of March 31, 2014, two customers represented 26% and 25% (total of 51%) of the Company’s accounts receivable.
	As of December 31, 2013, three customers represented 20%, 20% and 36% (total 76%) of the Company’s accounts receivable.
	For the three months ended March 31, 2014, the Company’s revenues earned from the sale of products and services were $322,572, of which two customers represented 17% and 10% of the Company’s revenues.
Research and Development	'
	Research and Development
	The Company accounts for research and development costs in accordance with Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved as defined under the applicable agreement. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $9,857 and $163,974 for the three months ended March 31, 2014 and 2013, respectively; and $65,329,892 from August 12, 1999 (date of inception) to March 31, 2014.
Fair Value	'
	Fair Value
	Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities, and short-term borrowings, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed.
	The company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value. Neither of these statements had an impact on the Company’s financial position, results of operations nor cash flows.
Reliance on Key Personnel and Consultants	'
	Reliance on Key Personnel and Consultants
	The Company has 4 full-time employees and 1 part-time employee. The Company is heavily dependent on the continued active participation of these current executive officers, employees and key consultants. The loss of any of the senior management or key consultants could significantly and negatively impact the business until adequate replacements can be identified and put in place.
Derivative Instrument Liability	'
	Derivative Instrument Liability
	The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At March 31, 2014 and December 31, 2013, the Company did not have any derivative instruments that were designated as hedges.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s unaudited condensed financial position, results of operations or cash flows.

Property_and_Equipment_Tables

Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2014
Property and Equipment [Abstract]	'
Summary of property and equipment	'
		March 31,			December 31,
		2014			2013
	Laboratory and medical equipment	$	352,358		$	352,358
	Furniture, fixtures and equipment		125,634			125,634
	Computer equipment		39,525			39,525
	Leasehold improvements		362,046			362,046
			879,563			879,563
	Less accumulated depreciation and amortization		(871,371	)		(870,508	)
		$	8,192		$	9,055

Accrued_Expenses_Tables

Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2014
Accrued Expenses [Abstract]	'
Summary of accrued expenses	'
		March 31,		December 31,
		2014		2013
	License and royalty fees	$	—	$	2,122,130
	Amounts payable to the Guarantors of the Company’s loan agreement with Bank of America and Seaside Bank, including fees and interest		1,356,013		1,373,775
	Interest payable on notes payable		757,669		714,180
	Vendor accruals and other		127,189		120,692
	Employee commissions, compensation, etc.		127,506		149,558
		$	2,368,377	$	4,480,335

Notes_Payable_Tables

Notes Payable (Tables)	3 Months Ended
	Mar. 31, 2014
Notes Payable [Abstract]	'
Summary of notes payable	'
		March 31,			December 31,
		2014			2013
	Seaside Bank note payable.	$	980,000		$	980,000
	August 2008 Unsecured Promissory Note		500,000			500,000
	Hunton & Williams notes payable		384,972			384,972
	Asher notes payable		183,000			143,000
	Daniel James Management note payable		35,000
	Fourth Man, LLC note payable		35,000			35,000
	Total notes payable		2,117,972			2,042,972
	Less unamortized debt discount		(151,027	)		(112,131	)
	Total notes payable net of unamortized debt discount	$	1,966,946		$	1,930,841

Stock_Option_and_Warrants_Tabl

Stock Option and Warrants (Tables)	3 Months Ended
	Mar. 31, 2014
Stock Options and Warrants [Abstract]	'
Summary of options and activity	'
					Weighted-		Weighted-
		Shares			Average		Average
					Exercise Price		Remaining
							Contractual
							Term (in years)
	Options outstanding at January 1, 2013		7,853,376		$	0.67		8.2
	Granted		17,400,000		$	0.016		9.9
	Exercised		—				$
	Forfeited/Expired		(1,340,433	)	$	1.08
	Options outstanding at December 31, 2013		23,912,943		$	0.15		9
	Granted		19,800,000		$	0.019		9.1
	Exercised		—
	Forfeited/Expired		(62,087	)	$	1.08
	Options outstanding at March 31, 2014		43,650,856		$	0.08		9.3
	Options exercisable at March 31, 2014		16,650,856		$	0.18		8.9
	Available for grant at March 31, 2014		12,800,000
Summary of options outstanding and exercisable for stock-based payment awards	'
		Options Outstanding							Options Exercisable
								Weighted-		Shares			Weighted-
			Shares			Weighted-		Average					Average
						Average		Exercise					Exercise
						Remaining		Price					Price
						Contractual
						Term
	$0.00 – $0.70		43,090,000			9.4	$	0.03		16,090,000		$	0.04
	$0.71 – $1.28		162,286			4.2	$	0.8		162,286		$	0.8
	$5.25 – $5.67		373,858			2.1	$	5.55		373,858		$	5.55
	$7.69		24,712			2.3	$	7.69		24,712		$	7.69
			43,650,856			9.3	$	0.08		16,650,856		$	0.18
Summary of warrants and activity	'
		Shares			Weighted-		Weighted-
					Average		Average
					Exercise		Remaining
					Price		Contractual
							Term (in
							years)
	Outstanding at January 1, 2013		74,073,322		$	0.37		4.5
	Issued		50,350,536		$	0.16		9.2
	Exercised		—		$	0
	Forfeited		-6,345,002		$	0.38
	Outstanding at December 31, 2013		118,078,856		$	0.22		6.3
	Issued		32,292,783		$	0.017		8.4
	Exercised		—		$	—
	Expired		(2,314,575	)	$	0.18
	Outstanding at March 31, 2014		148,057,064		$	0.17		6.7
	Exercisable at March 31, 2014		102,401,650		$	0.13		5.7
Summary of warrants outstanding and exercisable	'
		Warrants Outstanding							Warrants Exercisable
		Shares			Weighted-		Weighted-		Shares		Weighted-
					Average		Average				Average
					Remaining		Exercise				Exercise
					Contractual		Price				Price
					Term
	$0.01 – $0.50		141,807,931			6.7	$	0.02		97,696,967		$	0.02
	$0.52 – $0.68		2,699,675			5.1	$	0.58		2,699,675		$	0.58
	$0.70 – $1.62		848,176			5.8	$	0.71		848,176		$	0.71
	$5.67 – $7.69		2,701,282			8.6	$	7.55		1,156,832		$	7.35
			148,057,064			6.7	$	0.17		102,401,650		$	0.13

Fair_Value_Measurement_Tables

Fair Value Measurement (Tables)	3 Months Ended
	Mar. 31, 2014
Fair Value Measurement [Abstract]	'
Summary of changes in fair value of the Company's Level 3 financial liabilities	'
			Excess Share			Warrant			Debt
			Derivative			Liability			Derivative
	Balance, December 31, 2012	$	390,048			221,179		$	—
	Total (gains) losses
	Initial fair value of debt derivative at note issuance					—			673,219
	Initial fair value of derivative relating to reset warrants		—			—			—
	Mark-to-market at December 31, 2013:		84.906			(74,324	)		(39,761	)
	Transfers out of Level 3 upon increase in authorized shares		(474,954	)		—			—
	Transfers out of Level 3 upon conversion and settlement of notes								(376,502	)
	Balance, December 31, 2013	$	—		$	146,855		$	256,956
	Total (gains) losses
	Initial fair value of debt derivative at note issuance		—			—			292,257
	Mark-to-market at March 31, 2014:		—			519,630			(30,259	)
	Transfers out of Level 3 upon conversion of notes payable		—			—			(134,243	)
	Balance, March 31, 2014	$	—		$	666,485		$	384,711
	Net (Loss) Gain for the period included in earnings relating to the liabilities held at March 31, 2014	$	—		$	(519,630	)	$	30,259

Significant_Accounting_Policie2

Significant Accounting Policies (Details) (USD $)

3 Months Ended

176 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Dec. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Employees

Employee Stock Option [Member]

Employee Stock Option [Member]

Employee Stock Option [Member]

Accounts Receivable [Member]

Accounts Receivable [Member]

Accounts Receivable [Member]

Accounts Receivable [Member]

Accounts Receivable [Member]

Accounts Receivable [Member]

Accounts Receivable [Member]

Sales Revenue Goods and Services Net [Member]

Sales Revenue Goods and Services Net [Member]

Sales Revenue Goods and Services Net [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer One [Member]

Customer One [Member]

Customer Two [Member]

Customer Two [Member]

Customer Three [Member]

Customer Concentration Risk [Member]

Customer One [Member]

Customer Two [Member]

Customer

Customer

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Significant Accounting Policies (Textual)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Concentration Risk, Percentage

'

'

'

'

'

'

'

51.00%

76.00%

26.00%

20.00%

25.00%

20.00%

36.00%

'

17.00%

10.00%

Number of customer accounted for accounts receivable

'

'

'

'

'

'

'

2

3

'

'

'

'

'

'

'

'

Revenue

$322,572

$4,192

$1,688,297

'

'

'

'

'

'

'

'

'

'

'

$322,572

'

'

Number of customers accounted for revenue

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2

'

'

Deficit accumulated during development stage

117,503,543

'

117,503,543

118,180,983

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of fully diluted shares outstanding

498,696,292

185,421,093

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Option outstanding to purchase common stock

'

'

'

'

43,650,856

23,912,943

7,853,376

'

'

'

'

'

'

'

'

'

'

Options vested

'

'

'

'

16,650,856

'

'

'

'

'

'

'

'

'

'

'

'

Number of full time employees

4

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of part time employees

1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Research and development expense

$9,857

$163,974

$65,329,892

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Going_Concern_Matters_Details

Going Concern Matters (Details) (USD $)	3 Months Ended		176 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014
Going Concern Matters (Textual)	'	'	'
Net losses attributable to common shareholders	$620,923	'	'
Net cash used in operating activities	-257,762	-546,378	-75,135,166
Working capital deficit	$11,100,000	'	$11,100,000

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Summary of property and equipment	'	'
Laboratory and medical equipment	$352,358	$352,358
Furniture, fixtures and equipment	125,634	125,634
Computer equipment	39,525	39,525
Leasehold improvements	362,046	362,046
Property and equipment, Gross	879,563	879,563
Less accumulated depreciation and amortization	-871,371	-870,508
Property and equipment, net	$8,192	$9,055

Accrued_Expenses_Details

Accrued Expenses (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Summary of accrued expenses	'	'
License and royalty fees	'	$2,122,130
Amounts payable to the Guarantors of the Company's loan agreement with Bank of America and Seaside Bank, including fees and interest	1,356,013	1,373,775
Interest payable on notes payable	757,669	714,180
Vendor accruals and other	127,189	120,692
Employee commissions, compensation, etc.	127,506	149,558
Accrued expenses, Total	$2,368,377	$4,480,335

Accrued_Expenses_Details_Textu

Accrued Expenses (Details Textual) (USD $)	3 Months Ended
	Mar. 31, 2014
Accrued Expenses (Textual)	'
Shares issued in conversion of debt	6,750,781
Settlement of debt related to Accural Interest	$2,122,130
Loss on settlement of debt.	$65,548

Standby_Equity_Distribution_Ag1

Standby Equity Distribution Agreement (Details) (USD $)	0 Months Ended
In Millions, unless otherwise specified	Nov. 02, 2011
Standby Equity Distribution Agreement (Textual)	'
Funds contributed by Greystone	$1
Period for which funding is provided	'24 months

Notes_Payable_Details

Notes Payable (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013	Aug. 20, 2008
Summary of notes payable	'	'	'
Total notes payable	$2,117,972	$2,042,972	'
Less unamortized debt discount	-151,027	-112,131	'
Total notes payable net of unamortized debt discount	1,966,946	1,930,841	'
Seaside Bank note payable [Member]	'	'	'
Summary of notes payable	'	'	'
Total notes payable	980,000	980,000	'
August 2008 Unsecured Promissory Note [Member]	'	'	'
Summary of notes payable	'	'	'
Total notes payable	500,000	500,000	1,000,000
Hunton & Williams notes payable [Member]	'	'	'
Summary of notes payable	'	'	'
Total notes payable	384,972	384,972	'
Asher notes payable [Member]	'	'	'
Summary of notes payable	'	'	'
Total notes payable	183,000	143,000	'
Fourth Man, LLC note payable [Member]	'	'	'
Summary of notes payable	'	'	'
Total notes payable	35,000	35,000	'
Daniel James management note payable [Member]	'	'	'
Summary of notes payable	'	'	'
Total notes payable	$35,000	'	'

Notes_Payable_Details_Textual

Notes Payable (Details Textual) (USD $)

3 Months Ended

12 Months Ended

176 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

3 Months Ended

3 Months Ended

0 Months Ended

Mar. 31, 2014

Mar. 31, 2013

Dec. 31, 2013

Mar. 31, 2014

Oct. 25, 2010

Mar. 31, 2014

Dec. 31, 2013

Apr. 30, 2009

Aug. 20, 2008

Dec. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Feb. 19, 2014

Dec. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Feb. 19, 2014

Mar. 31, 2014

Seaside Bank note payable [Member]

Seaside Bank note payable [Member]

Seaside Bank note payable [Member]

August 2008 Unsecured Promissory Note [Member]

August 2008 Unsecured Promissory Note [Member]

August 2008 Unsecured Promissory Note [Member]

August 2008 Unsecured Promissory Note [Member]

Hunton & Williams notes payable [Member]

Hunton & Williams notes payable [Member]

Hunton & Williams notes payable [Member]

Hunton & Williams notes payable [Member]

Hunton & Williams notes payable [Member]

Hunton & Williams notes payable [Member]

Asher notes payable [Member]

Asher notes payable [Member]

Asher notes payable [Member]

Asher notes payable [Member]

Asher notes payable [Member]

Asher notes payable [Member]

Asher notes payable [Member]

Daniel Note [Member]

Daniel Note [Member]

Notes_Payable

Notes_Payable

Note payable one [Member]

Note payable one [Member]

Note payable two [Member]

Note payable two [Member]

Daniel James Management [Member]

Daniel James Management [Member]

Daniel James Management [Member]

Daniel James Management [Member]

Maximum [Member]

Minimum [Member]

Notes Payable (Textual)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net of unamortized debt discount

$151,027

'

$112,131

$151,027

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Notes payable

2,117,972

'

2,042,972

2,117,972

'

980,000

980,000

'

1,000,000

500,000

500,000

384,972

384,972

'

'

'

'

183,000

'

143,000

'

'

'

'

'

'

Common stock issued in connection with issuance of a note payable, Shares

'

'

'

'

980,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Effective interest rate

'

'

'

'

4.25%

'

'

'

13.50%

'

'

'

'

8.00%

8.00%

8.00%

8.00%

8.00%

'

'

'

'

'

'

8.00%

'

Notes payable, net of debt discount

1,966,946

'

1,930,841

1,966,946

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument, Maturity date

'

'

'

'

'

'

'

'

31-May-10

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gross proceeds from private placement

'

'

'

'

'

'

'

'

19,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Occurrence period of repayment of loan

'

'

'

'

'

'

'

'

'within 12 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrant issued to purchase common stock

'

'

'

'

'

'

'

451,053

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrant exercise price

'

'

'

'

'

'

'

$0.53

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of warrant issued

'

'

'

'

'

'

'

195,694

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of outstanding notes payable

'

'

'

'

'

'

'

'

'

'

'

2

2

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding notes payable

'

'

'

'

'

'

'

'

'

'

'

'

'

61,150

61,150

323,822

323,822

'

'

'

'

'

'

'

'

'

Accrued interest

'

'

598,125

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares issued in conversion of debt

6,750,781

'

'

'

'

'

'

'

'

1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gain (loss) on settlement of note payable

'

'

1,078,625

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Description of note payable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'The Notes are convertible into common stock, at Asher's option, at a 45% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion. The Company has identified the embedded derivatives related to the Asher Notes.

'

'

'

'

'

'

'

'

Fair value of embedded derivatives

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

214,346

'

292,257

'

'

'

'

63,343

Recorded fair value of derivatives and faire value of each subsequent reporting date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

153,564

'

'

'

'

'

'

'

63,343

Outstanding principal amount of debt

349,413

'

'

349,413

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amortization of debt discount

93,604

124,838

'

2,073,854

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

127,500

'

'

'

'

'

Interest expense

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

164,757

'

'

'

'

'

Dividend yield

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.00%

'

'

'

'

'

Expected volatility

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

181.73%

158.19%

'

'

Risk free rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.15%

0.03%

'

'

Expected Term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'1 year

'11 days

'

'

Estimated fair value of the Company's common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.04

$0.00

'

'

Notes payable, Principle value

'

'

'

'

'

'

'

'

'

500,000

'

'

'

'

'

'

'

97,500

'

'

'

'

'

'

'

'

Common shares issued in conversion of debt

6,750,781

'

'

'

'

'

'

'

'

1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amortization of financing costs and discounts

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

93,604,000

124,838

'

'

'

'

Convertible note in principal amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$35,000

'

Related_Party_Transaction_Deta

Related Party Transaction (Details) (USD $)

Mar. 31, 2014

Dec. 31, 2013

Oct. 01, 2012

Sep. 21, 2012

Feb. 28, 2013

Dec. 31, 2012

Mar. 31, 2014

Dec. 31, 2013

Feb. 29, 2012

Mar. 30, 2012

Oct. 09, 2012

Mar. 31, 2014

Dec. 31, 2013

Aug. 01, 2013

Nov. 30, 2012

Oct. 22, 2012

Jun. 04, 2011

Mar. 31, 2014

Mar. 31, 2014

Northstar Biotechnology Group, LLC Promissory Note [Member]

Northstar Biotechnology Group, LLC Promissory Note [Member]

Northstar Biotechnology Group, LLC Promissory Note [Member]

Northstar Biotechnology Group, LLC Promissory Note [Member]

Northstar Biotechnology Group, LLC Promissory Note [Member]

Northstar Biotechnology Group, LLC Promissory Note [Member]

Northstar Biotechnology Group, LLC Promissory Note [Member]

Promissory Note [Member]

Officer and Director [Member]

Officer and Director [Member]

Officer and Director [Member]

Officer and Director [Member]

Officer and Director [Member]

Officer and Director [Member]

Officer and Director [Member]

Officer and Director [Member]

Officer and Director [Member]

Minimum [Member]

Maximum [Member]

Related Party Transactions (Textual)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Advances, related party

$403,957

$416,198

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding principal amount of debt

349,413

'

'

'

'

'

362,000

362,000

544,267

'

'

'

'

'

'

'

'

'

'

Repayment terms

'

'

'

'

'

'

'

'

'

'The first of the four monthly payments required under the Note will be due and payable on May, 2012 and all subsequent payments will be due on a monthly basis thereafter commencing on June 1, 2012.

'

'

'

'

'

'

'

'

'

Common stock purchase warrants issued

'

'

'

5,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Series A convertible preferred stock issued in exchange for payments

'

'

5,000,000

'

'

5,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued in exchange for payments

'

'

10,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Value of debt outstanding

'

'

210,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of revenues to be received as royalty

'

'

8.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Effective interest rate

'

'

12.85%

'

7.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Subordinated debt, related party

1,500,000

1,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Effective interest rate

'

'

'

'

'

'

'

'

'

'

5.00%

8.00%

8.00%

5.00%

'

'

'

4.75%

8.00%

Subordinated notes

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

125,000

140,000

'

'

Face value of note

'

'

'

'

'

'

'

'

'

'

1,278,324

'

'

500,000

'

'

'

'

'

Debt instrument, Maturity date

'

'

'

'

'

'

'

'

'

'

9-Oct-13

'

'

'

'

'

'

'

'

Common Stock, Voting Rights

'

'

'

'

'

'25 votes

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Voting Rights

'

'

'

'

'

'20 votes

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued in settlement of related party notes payable,Shares

'

'

'

'

'

'

'

'

'

'

'

15,350,876

'

'

'

'

'

'

'

Common stock issued in settlement of related party notes payable

'

'

'

'

'

'

'

'

'

'

'

175,000

'

'

'

'

'

'

'

Outstanding promissory notes

$63,740

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Derivative_Liabilities_Details

Derivative Liabilities (Details) (USD $)	2 Months Ended	3 Months Ended
	Oct. 31, 2012	Mar. 31, 2014	Oct. 01, 2012
Reset Warrants [Member]	'	'	'
Derivative Liabilities (Textual)	'	'	'
Fair value of derivative liability	'	$666,485	'
Dividend yield	'	0.00%	'
Expected volatility	'	173.72%	'
Risk free rate	'	2.73%	'
Expected Term	'	'8 years 6 months	'
Loss on change in derivative liabilities	'	519,630	'
Common stock purchase warrants issued	15,000,000	'	'
Exercise price of warrant	'	'	0.014
Warrants exercisable period	'	'	'10 years
Convertible Notes Payable [Member]	'	'	'
Derivative Liabilities (Textual)	'	'	'
Fair value of derivative liability	'	1,051,196	'
Fair value of embedded derivatives	'	384,711	'
Dividend yield	'	0.00%	'
Expected volatility	'	173.72%	'
Loss on change in derivative liabilities	'	$30,259	'
Fair value of common stock	'	$0.04	'
Convertible Notes Payable [Member] | Minimum [Member]	'	'	'
Derivative Liabilities (Textual)	'	'	'
Risk free rate	'	0.03%	'
Expected Term	'	'11 days	'
Convertible Notes Payable [Member] | Maximum [Member]	'	'	'
Derivative Liabilities (Textual)	'	'	'
Risk free rate	'	0.13%	'
Expected Term	'	'8 months 27 days	'

Stockholders_Equity_Details

Stockholders' Equity (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Aug. 17, 2012
		Series A Convertible Preferred Stock [Member]
Stockholders Equity (Textual)	'	'
Preferred stock designated as Series A Convertible Preferred Stock	'	5,000,000
Preferred stock shares increased	'	20,000,000
Loss on settlement of debt.	$65,548	'
Issuance of common stock, Shares	6,750,781	'
Common stock issued upon conversion of notes payable and accured interest, Share	7,166,214	'
Common stock issued upon conversion of notes payable	57,500	'
Common stock issued upon conversion of accrued interest.	$2,300	'

Stock_Option_and_Warrants_Deta

Stock Option and Warrants (Details) (Stock Options [Member], USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Stock Options [Member]	'	'	'
Summary of options and activity	'	'	'
Options outstanding, Beginning Balance	23,912,943	7,853,376	'
Granted, shares	19,800,000	17,400,000	'
Exercised, Shares	'	'	'
Forfeited/Expired, Shares	-62,087	-1,340,433	'
Options outstanding, Ending Balance	43,650,856	23,912,943	7,853,376
Options Exercisable, Shares	16,650,856	'	'
Available for grant, Shares	12,800,000	'	'
Options outstanding, Weighted - Average Exercise Price, Beginning Balance	$0.15	$0.67	'
Granted, Weighted - Average Exercise Price	$0.02	$0.02	'
Forfeited/Expired, Weighted - Average Exercise Price	$1.08	$1.08	'
Options outstanding, Weighted - Average Exercise Price, Balance	$0.08	$0.15	$0.67
Options exercisable, Weighted - Average Exercise Price	$0.18	'	'
Options Exercised, Weighted - Average Remaining Contractual Term	'9 years 1 month 6 days	'9 years 10 months 24 days	'
Options outstanding, Weighted - Average Remaining Contractual Term (in years)	'9 years 3 months 18 days	'9 years	'8 years 2 months 12 days
Options exercisable, Weighted - Average Remaining Contractual Term (in years)	'8 years 10 months 24 days	'	'

Stock_Option_and_Warrants_Deta1

Stock Option and Warrants (Details 1) (Stock Options [Member], USD $)	3 Months Ended
	Mar. 31, 2014
Options outstanding and exercisable for stock-based payment awards	'
Options Outstanding, Shares	43,650,856
Options Outstanding, Weighted-Average Remaining Contractual Term	'9 years 3 months 18 days
Options Outstanding, Weighted- Average Exercise Price	$0.08
Options Exercisable, Shares	16,650,856
Options Exercisable, Weighted-Average Exercise Price	$0.18
$0.00 - $0.70 [Member]	'
Options outstanding and exercisable for stock-based payment awards	'
Range of Exercise Prices, Minimum	$0
Range of Exercise Prices, Maximum	$0.70
Options Outstanding, Shares	43,090,000
Options Outstanding, Weighted-Average Remaining Contractual Term	'9 years 4 months 24 days
Options Outstanding, Weighted- Average Exercise Price	$0.03
Options Exercisable, Shares	16,090,000
Options Exercisable, Weighted-Average Exercise Price	$0.04
$0.71 - $1.28 [Member]	'
Options outstanding and exercisable for stock-based payment awards	'
Range of Exercise Prices, Minimum	$0.71
Range of Exercise Prices, Maximum	$1.28
Options Outstanding, Shares	162,286
Options Outstanding, Weighted-Average Remaining Contractual Term	'4 years 2 months 12 days
Options Outstanding, Weighted- Average Exercise Price	$0.80
Options Exercisable, Shares	162,286
Options Exercisable, Weighted-Average Exercise Price	$0.80
$5.25 - $5.67 [Member]	'
Options outstanding and exercisable for stock-based payment awards	'
Range of Exercise Prices, Minimum	$5.25
Range of Exercise Prices, Maximum	$5.67
Options Outstanding, Shares	373,858
Options Outstanding, Weighted-Average Remaining Contractual Term	'2 years 1 month 6 days
Options Outstanding, Weighted- Average Exercise Price	$5.55
Options Exercisable, Shares	373,858
Options Exercisable, Weighted-Average Exercise Price	$5.55
$7.69 [Member]	'
Options outstanding and exercisable for stock-based payment awards	'
Range of Exercise Prices	$7.69
Options Outstanding, Shares	24,712
Options Outstanding, Weighted-Average Remaining Contractual Term	'2 years 3 months 18 days
Options Outstanding, Weighted- Average Exercise Price	$7.69
Options Exercisable, Shares	24,712
Options Exercisable, Weighted-Average Exercise Price	$7.69

Stock_Option_and_Warrants_Deta2

Stock Option and Warrants (Details 2) (Warrant [Member], USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Warrant [Member]	'	'
Summary of warrants and activity	'	'
Options outstanding, Beginning Balance	118,078,856	74,073,322
Options outstanding, Weighted - Average Exercise Price, Beginning Balance	$0.22	$0.37
Warrants outstanding, Weighted - Average Remaining Contractual Term (in years)	'	'4 years 6 months
Shares, issued	32,292,783	50,350,536
Warrants, Weighted-Average Exercise Price	$0.02	$0.16
Warrants, Weighted Average Remaining Contractual Term (in years)	'8 years 4 months 24 days	'9 years 2 months 12 days
Exercised, Shares	'	'
Exercised, Weighted - Average Exercise Price	'	$0
Forfeited/Expired, Shares	-2,314,575	-6,345,002
Forfeited/Expired, Weighted - Average Exercise Price	$0.18	$0.38
Options outstanding, Ending Balance	148,057,064	118,078,856
Options outstanding, Weighted - Average Exercise Price, Balance	$0.17	$0.22
Options outstanding, Weighted - Average Remaining Contractual Term	'6 years 8 months 12 days	'6 years 3 months 18 days
Options Exercisable, Shares	102,401,650	'
Options exercisable, Weighted - Average Exercise Price	$0.13	'
Warrants exercisable, Weighted - Average Remaining Contractual Term (in years)	'5 years 8 months 12 days	'

Stock_Option_and_Warrants_Deta3

Stock Option and Warrants (Details 3) (Warrant [Member], USD $)	3 Months Ended
	Mar. 31, 2014
Warrants outstanding and exercisable	'
Warrants Outstanding, Shares	148,057,064
Warrants Outstanding, Weighted-Average Remaining Contractual Term	'6 years 8 months 12 days
Warrants Outstanding, Weighted- Average Exercise Price	$0.17
Warrants Exercisable, Shares	102,401,650
Warrants Exercisable, Weighted-Average Exercise Price	$0.13
0.01 - $0.50 [Member]	'
Warrants outstanding and exercisable	'
Warrants Outstanding, Shares	141,807,931
Warrants Outstanding, Weighted-Average Remaining Contractual Term	'6 years 8 months 12 days
Warrants Outstanding, Weighted- Average Exercise Price	$0.02
Warrants Exercisable, Shares	97,696,967
Warrants Exercisable, Weighted-Average Exercise Price	$0.02
0.52 - $0.68 [Member]	'
Warrants outstanding and exercisable	'
Warrants Outstanding, Shares	2,699,675
Warrants Outstanding, Weighted-Average Remaining Contractual Term	'5 years 1 month 6 days
Warrants Outstanding, Weighted- Average Exercise Price	$0.58
Warrants Exercisable, Shares	2,699,675
Warrants Exercisable, Weighted-Average Exercise Price	$0.58
0.70 - $1.62 [Member]	'
Warrants outstanding and exercisable	'
Warrants Outstanding, Shares	848,176
Warrants Outstanding, Weighted-Average Remaining Contractual Term	'5 years 9 months 18 days
Warrants Outstanding, Weighted- Average Exercise Price	$0.71
Warrants Exercisable, Shares	848,176
Warrants Exercisable, Weighted-Average Exercise Price	$0.71
5.67 - $7.69 [Member]	'
Warrants outstanding and exercisable	'
Warrants Outstanding, Shares	2,701,282
Warrants Outstanding, Weighted-Average Remaining Contractual Term	'8 years 7 months 6 days
Warrants Outstanding, Weighted- Average Exercise Price	$7.55
Warrants Exercisable, Shares	1,156,832
Warrants Exercisable, Weighted-Average Exercise Price	$7.35

Stock_Option_and_Warrants_Deta4

Stock Option and Warrants (Details Textual) (USD $)	3 Months Ended		0 Months Ended		3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Feb. 24, 2014	Feb. 24, 2014	Mar. 31, 2014
			Officer [Member]	Officer One [Member]	Warrant [Member]
Stock Options and Warrants (Textual)	'	'	'	'	'
Options to purchase the Company's common stock	'	'	15,000,000	4,800,000	'
Exercise price	'	'	$0.02	$0.02	'
Stock option vesting right percentage	'	'	25.00%	'	'
Stock option exercisable period	'	'	'10 years	'10 years	'
Fair value of the option vested	$194,565	$19,632	$282,597	$90,431	'
Dividend yield	'	'	0.00%	0.00%	'
Volatility	'	'	163.63%	163.63%	'
Risk free rate	'	'	2.75%	2.75%	'
Share based compensation shares authorized	'	'	'	'	24,292,783
Warrants issued	'	'	'	'	8,000,000
Fair value of vested warrants	'	'	'	'	$22,546
Warrant vesting period description	'	'	'	'	'Vesting from June 8, 2014 through March 10, 2015
Warrants exercise price	'	'	'	'	$0.02
Warrant vesting period	'	'	'	'	'4 years

Commiments_and_Contingencies_D

Commiments and Contingencies (Details Textual) (USD $)	1 Months Ended	3 Months Ended		1 Months Ended
	Jun. 30, 2000	Mar. 31, 2014	Mar. 31, 2014	Nov. 20, 2013	Mar. 31, 2014	Dec. 31, 2013
			Warrant [Member]	Warrant [Member]	Warrant [Member]	Warrant [Member]
				Consulting Agreements [Member]	Consulting Agreements [Member]	Consulting Agreements [Member]
Commitments and Contingencies (Textual)	'	'	'	'	'	'
Warrants issued	'	'	8,000,000	'	'	'
Fair value of vested warrants	'	'	$22,546	'	'	'
Warrants exercise price	'	'	$0.02	$0.01	'	'
Warrants vesting description	'	'	'2,000,000 warrants vesting 90 days from the effective date, 2,000,000 vesting on each anniversary date for three years.	'	'	'
Warrant exercise period	'	'	'4 years	'10 years	'	'
Warrant expected to vest in future period	'	'	2,000,000	'	'	'
Patent expiration period	'2015	'	'	'	'	'
Accrued expenses	'	2,122,000	'	'	46,317	32,424
Repurchase consideration for unexercised options	'	'77% of the option exercise price multiplied by the number of option shares, plus interest at the rate of 7% from the date the options were granted.	'	'	'	'
Total rescission liability	'	$371,000	'	'	'	'
Fess received by Cassel Salpeter & Co	'	'	'	'CSC will receive a one-time $25,000 fee, $5,000 monthly fees.	'	'
Common stock purchase warrants	'	'	'	5,207,630	'	'

Fair_Value_Measurement_Details

Fair Value Measurement (Details) (USD $)	3 Months Ended		176 Months Ended	3 Months Ended	12 Months Ended	3 Months Ended	12 Months Ended	3 Months Ended	12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Dec. 31, 2013
				Excess Share Derivative [Member]	Excess Share Derivative [Member]	Warrant [Member]	Warrant [Member]	Derivative [Member]	Derivative [Member]
Summary of changes in fair value of the Company's Level 3 financial liabilities	'	'	'	'	'	'	'	'	'
Beginning Balance	'	'	'	'	$390,048	$146,855	$221,179	$256,956	'
Total (gains) losses	'	'	'	'	'	'	'	'	'
Initial fair value of debt derivative at note issuance	'	'	'	'	'	'	'	292,257	673,219
Initial fair value of derivative relating to reset warrants	'	'	'	'	'	'	'	'	'
Mark-to-market	'	'	'	'	84.906	519,630	-74,324	-30,259	-39,761
Transfers out of Level 3 upon increase in authorized shares	'	'	'	'	-474,954	'	'	'	'
Transfers out of Level 3 upon conversion and settlement of notes	'	'	'	'	'	'	'	'	-376,502
Transfers out of Level 3 upon conversion of notes payable	'	'	'	'	'	'	'	-134,243	'
Balance	1,051,196	'	1,051,196	'	'	666,485	146,855	384,711	256,956
Net (Loss) Gain for the period included in earnings relating to the liabilities held at March 31, 2014	($489,371)	($640,589)	($365,423)	'	'	($519,630)	'	$30,259	'

Fair_Value_Measurement_Details1

Fair Value Measurement (Details Textual) (USD $)	3 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Fair Value Measurement (Textual)	'	'
Derivative Instruments and Hedges, Liabilities	$0	$0
Derivative liability	$1,051,196	'
Percentage of stock price increase	447.00%	'

Subsequent_Events_Details

Subsequent Events (Details) (USD $)	1 Months Ended	3 Months Ended
	Apr. 30, 2014	Mar. 31, 2014
Subsequent Events (Textual)	'	'
Common stock issued for settlement of convertible note payable and accrued interest, shares	'	6,750,781
Accrued interest	'	$2,122,130
Subsequent Event [Member]	'	'
Subsequent Events (Textual)	'	'
Common stock issued for services,Shares	3,839,832	'
Common stock issued for services	43,250	'
Common stock issued for related party advance	100,000	'
Common stock issued for related party advance, shares	5,263,315	'
Common Stock issued with connection of stock subcriptions, shares	1,002,808	'
Common Stock issued with connection of stock subcriptions	50,000	'
Common stock issued in settlement of accrued interest, Shares	274,681	'
Common stock issued for service rendered	180,511	'
Common stock issued for service rendered, shares	18,383,774	'
Common stock issued for settlement of convertible note payable and accrued interest	67,500	'
Common stock issued for settlement of convertible note payable and accrued interest, shares	4,793,268	'
Accrued interest	2,700	'
Common stock issued for exercise of warrants, shares	11,918,181	'
Common stock issued for exercise of warrants	$136,000	$6,000